8.58

8.58 (0.03%)

As of Jan 14, 2022

Annexon, Inc. [ANNX]

Source: 

Company Overview

We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. C1q, the initiating molecule of the classical complement pathway, is a core component to the body’s immune system that activates a powerful inflammatory cascade.

CountryUS
Headquartersbrisbanecalifornia
Phone Number(650) 822-5500
Industrypharmaceutical preparations
CEODouglas Love, Esq.
Websitewww.annexonbio.com